Method of using vasoconstrictive agents during energy-based tissue therapy
A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.
1 . An ablation method comprising the step of administering to a mammalian subject undergoing an ablation procedure at least one adenosine receptor antagonist in an amount effective to prevent and minimize vasodilation associated with an elevated concentration of adenosine in the mammalian subject.
2 . A method according to claim 1 , wherein the ablation procedure produces a coagulation zone having a radius.
3 . A method according to claim 2 , wherein the radius has a length of about 1 cm to about 15 cm.
4 . A method according to claim 2 , wherein the radius is greater than 1 cm.
5 . A method according to claim 1 , wherein the at least one adenosine receptor antagonist comprises at least one of aminophylline, 8SPT, MRS1754, MRS1220, MRE3008F20, MRS1523, and ATL146e.
6 . A method according to claim 1 , wherein in vivo, the at least one adenosine receptor antagonist binds to at least one adenosine receptor.
7 . A method according to claim 1 , wherein the at least one adenosine receptor antagonist is administered in a pharmaceutical composition that includes a pharmaceutically acceptable carrier or diluent.
8 . A method according to claim 1 , wherein the ablation is an energy-based tissue therapy.
9 . A method according to claim 8 , wherein the therapy is radio frequency energy-based tissue ablation.
10 . A method according to claim 1 , wherein the at least one adenosine receptor antagonist is at least one Al adenosine receptor antagonist.
11 . A method according to claim 10 , wherein the at least one A1 adenosine receptor antagonist is selected from the group consisting of 1,3-dipropyl-8-cyclopentylxanthine, 8-(4-[({[(2-aminoethyl)amino]carbonyl)oxy]-phenyl}-1,3-dipropylxanthine, N(6)-Endonorbornan-2-yl-9-methyladenine, ((S)-(−)-8-(3-Oxocyclopentyl)-1,3-dipropyl-7H-purine-2,6-dione), (3-[(4-amino)phenethyl]-8-cyclopentylexanthine, 1,3-dipropyl-8-(dicyclopropylmethyl)xanthine, and combinations thereof.
12 . A method according to claim 1 , wherein the at least one adenosine receptor antagonist is at least one A2 adenosine receptor antagonist.
13 . A method according to claim 12 , wherein the at least one A2 adenosine receptor antagonist is selected from the group consisting of 1,3-diallyl-8-(3,4,5-trimethoxystyryl)-7-methylxanthine, 8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 4-(2-[7-amino-2-(2-furyl[1,2,4]-triazolo[2,3-a[1,3,5]triazin-5-yl-)phenol),8-(3-Chlorostyryl)caffeine,E)-1,3-dipropyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine, enprofylline, 3-isobutyl-8-pyrrolidinoxanthine, [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]acetamide], and combinations thereof.
14 . A method according to claim 1 , wherein the adenosine receptor antagonist is at least one A3 adenosine receptor antagonist.
15 . A method according to claim 14 , wherein the at least one adenosine receptor antagonist is selected from the group consisting of 3,6-dichloro-2′-(isopropoxy)4′-methylflavone, 6-phenyl-1,4-dihydropyridines, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo [5,1-a][2,7]naphthyridine, (3-(4-methoxyphenyl)-5-amino-7-oxo-thiazolo [3,2]pyrimidine), 9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine, (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), and combinations thereof.
16 . A method of treating symptoms associated with adenosine comprising the step of administering to a mammalian subject undergoing an ablation procedure at least one adenosine receptor antagonist in an amount effective in preventing or alleviating vasodilation associated with adenosine.
17 . A method according to claim 16 , wherein the at least one adenosine receptor antagonist includes at least one of aminophylline, 8SPT, MRS1754, MRS1220, MRE3008F20, MRS1523, or ATL146e.
18 . An ablation method of treating vasodilation comprising the step of administering to a mammalian subject undergoing an ablation procedure at least one adenosine receptor antagonist in an amount effective in preventing or alleviating vasodilation, wherein the at least one adenosine receptor antagonist is selected from the group consisting of aminophylline, 8SPT, MRS1754, MRS1220, MRE3008F20, MRS1523, ATL146e, and combinations thereof.
19 . The method according to claim 18 , wherein the ablation method is a radiofrequency ablation of a cancer tumor.
20 . The method according to claim 18 , wherein the cancer tumor is located in liver, lung, or kidney tissue.
21 . A surgical technique comprising the step of:
administering at least one vasoconstrictive agent to a patient; and
performing an energy-based therapy to form a coagulation zone.
22 . A surgical technique in accordance with claim 21 , wherein the step of performing an energy-based therapy further comprises ablating tissue.
23 . A surgical technique in accordance with claim 21 wherein the energy-based therapy comprises cardiac ablation, transmyocardial revascularization, benign prostate hyperplasia therapy, ablation of endometriosis, breast cancer treatment, hemostasis, vessel sealing, endometrial ablation, skin resurfacing, metastasis ablation, image-guided treatments, noninvasive blood flow monitoring, surgical tissue welding, tissue reshaping, laser therapy, microwave therapy, radiofrequency therapy, high-intensity focused ultrasound therapy, cryotherapy therapy, conductive heating, or combinations thereof.